Molecular determinants of resistance to CDK4/6 inhibition in ER plus breast cancer

被引：0
|
作者：
Luo, F. [1 ,2 ]
Cowley, G. [3 ]
Garraway, L. [1 ,2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[2] Broad Inst, Med Oncol, Boston, MA USA
[3] Janssen Pharmaceut Co, Johnson & Johnson, Funct Genom, Discovery Sci, Perkasie, PA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
10.1016/S0959-8049(16)32819-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
224
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [21] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ehmsen, Sidse
    Tuttolomondo, Martina
    Terp, Mikkel G.
    Johansen, Lene E.
    Vever, Henriette
    Hoeg, Luna V. A.
    Elias, Daniel
    Bak, Martin
    Ditzel, Henrik J.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [22] Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
    Schedin, Troy B.
    Borges, Virginia F.
    Shagisultanova, Elena
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2018, 2018
  • [23] Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
    Scott, Susan Combs
    Lee, Sarah S.
    Abraham, Jame
    SEMINARS IN ONCOLOGY, 2017, 44 (06) : 385 - 394
  • [24] Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer
    Lenihan, C.
    Bouchekioua-Bouzaghou, K.
    Shia, A.
    Wilkes, E.
    Casado-Izguierdo, P.
    Cutillas, P.
    Schmid, P.
    CANCER RESEARCH, 2016, 76
  • [25] Pharmacological inhibition of CDK4/6 induces G1 arrest, autophagy and senescence in ER plus breast cancer
    Vijayaraghavan, Smruthi
    Keyomarsi, Khandan
    CANCER RESEARCH, 2015, 75
  • [26] CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard
    Wolff, Antonio C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20): : 1993 - 1995
  • [27] Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER plus breast cancer
    Sudhan, Dhivya R.
    Chatterjee, Sumanta
    Kim, Jiwoong
    Wang, Yunguan
    Kandagatla, Vishal
    Ye, Dan
    Lin, Chang-Ching
    Zanudo, Jorge Gomez Tejeda
    Jain, Esha
    Marin, Arnaldo
    Servetto, Alberto
    Lee, Kyung-min
    Povedano, Juan Manuel
    McFadden, David
    Barrett, Alex
    Wagle, Nikhil
    Hanker, Ariella B.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2022, 82 (04)
  • [28] EGFR signaling contributes to acquired resistance to CDK4/6 inhibitors in ER plus breast cancer cells in vitro and in vivo
    Lypova, Nadiia
    Lanceta, Lilibeth
    Daugherty, Susan
    Chesney, Jason
    Imbert-Fernandez, Yoannis
    CANCER RESEARCH, 2023, 83 (05)
  • [29] Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER plus breast cancer
    Mavrommati, Ioanna
    Moughari, Fatemeh Ahmadi
    Thakur, Shefali
    Zhang, Yu
    Martin, Lesley-Ann
    Haider, Syed
    Natrajan, Rachael
    CANCER RESEARCH, 2024, 84 (03)
  • [30] EGFR signaling as a mechanism of resistance to CDK4/6 inhibitors in Palbociclib-resistant ER plus breast cancer cells
    Lypova, Nadiia
    Lanceta, Lilibeth
    Dougherty, Susan M.
    Chesney, Jason A.
    Imbert-Fernandez, Yoannis
    CANCER RESEARCH, 2022, 82 (12)
12345